Neurocrine Biosciences (NBIX)
(Real Time Quote from BATS)
$139.31 USD
-0.78 (-0.56%)
Updated Apr 24, 2024 02:40 PM ET
2-Buy of 5 2
C Value A Growth F Momentum C VGM
Neurocrine Biosciences (NBIX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$147.42 | $200.00 | $100.00 | 5.23% |
Price Target
Based on short-term price targets offered by 24 analysts, the average price target for Neurocrine Biosciences comes to $147.42. The forecasts range from a low of $100.00 to a high of $200.00. The average price target represents an increase of 5.23% from the last closing price of $140.09.
Analyst Price Targets (24)
Broker Rating
Neurocrine Biosciences currently has an average brokerage recommendation (ABR) of 1.58 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 26 brokerage firms. The current ABR compares to an ABR of 1.50 a month ago based on 26 recommendations.
Of the 26 recommendations deriving the current ABR, 18 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 69.23% and 3.85% of all recommendations. A month ago, Strong Buy made up 73.08%, while Buy represented 3.85%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 18 | 18 | 19 | 19 | 19 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 7 | 6 | 6 | 6 | 6 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.58 | 1.52 | 1.50 | 1.50 | 1.50 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/23/2024 | Needham & Company | Ami Fadia | Not Available | Hold |
4/17/2024 | Wedbush Securities | Laura Chico | Strong Buy | Strong Buy |
4/10/2024 | Cantor Fitzgerald & Co | Josh Schimmer | Strong Buy | Strong Buy |
3/14/2024 | William Blair | Myles R Minter | Strong Buy | Strong Buy |
3/10/2024 | Guggenheim Securities | Yatin Suneja | Strong Buy | Strong Buy |
2/8/2024 | Mizuho SecuritiesUSA | Uy D Ear | Hold | Hold |
12/7/2023 | Canaccord Genuity | Sumant Kulkarni | Strong Buy | Strong Buy |
11/10/2023 | BMO Capital Markets | Evan Seigerman | Hold | Hold |
11/2/2023 | Raymond James | Danielle Brill | Moderate Buy | Moderate Buy |
11/1/2023 | H.C. Wainwright & Co. | Andrew S Fein | Strong Buy | Strong Buy |
10/31/2023 | SVB Securities | Marc Goodman | Strong Buy | Strong Buy |
8/2/2023 | Robert W. Baird & Co. | Brian P Skorney | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.58 |
ABR (Last week) | 1.52 |
# of Recs in ABR | 26 |
Average Target Price | $147.42 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 147 of 252 |
Current Quarter EPS Est: | 1.04 |